RxDoctor Payments DataLook up a doctor →

Allen Cohn, MD

Hematology & Oncology · Denver, CONPI 1316921976

Payments from drug & device makers

$13,538,881in general payments, 2019–2025

Across 2,110 payments — averaging $6416.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$3.5M
  • Novartis$3.5M
  • Amgen$1.6M
  • Aadi Bioscience, Inc.$702K
  • Eisai Inc.$650K
  • Genentech, Inc.$596K
  • plus $3M from 39 others
$2,850in research payments, 2019–2025

Across 3 payments — averaging $950.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$2K
  • EMD Serono, Inc.$1K

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,538,881 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$2,020,488
Medicare patients
536
Services billed
63,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →